Guanine Nucleosides - Potential New Therapeutic Uses

Cohen, Justin D.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: First Independent Research Support & Transition (FIRST) Awards (R29)
• Project #: 5R29CA062051-03
• Application #: 2103025
• Study Section: Experimental Therapeutics Subcommittee 1 (ET)
• Project Start: 1994-01-01
• Project End: 1998-12-31
• Budget Start: 1996-01-01
• Budget End: 1996-12-31
• Support Year: 3
• Fiscal Year: 1996

Institution

• Name: University of Colorado Denver
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 065391526
• City: Aurora
• State: CO
• Country: United States
• Zip Code: 80045

Publications

Cohen, J D; Strock, D J; Teik, J E et al. (1999) Clinically relevant deoxycytidine levels are high enough to profoundly alter 9-beta-D-arabinofuranosylguanine cytotoxicity for human T-cell acute leukemia cells in vitro. Pediatr Hematol Oncol 16:239-44

Cohen, J D; Strock, D J; LaGuardia, E A et al. (1998) Protection of leukemic cells by deoxycytidine: in vitro measures of protection against cytosine arabinoside. Leuk Res 22:421-7

Cohen, J D; Strock, D J; Teik, J E et al. (1997) Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy. Cancer Lett 116:167-75